ANI Pharmaceuticals
ANIP
138 hedge funds and large institutions have $313M invested in ANI Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 14 closing their positions.
143% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 14
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more capital invested
Capital invested by funds: $195M → $313M (+$118M)
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
14% more funds holding
Funds holding: 121 → 138 (+17)
5% more call options, than puts
Call options by funds: $12M | Put options by funds: $11.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$9.23M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$8.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$6.64M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.45M |
| 5 |
Renaissance Technologies
New York
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10.3M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$7.54M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.13M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$3.96M |
| 5 |
SG Americas Securities
New York
|
-$3.11M |
ANIP Hedge Fund Activity: Q2 2016 in Review
138 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2016, worth a combined $313M — up 60% from $195M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ANIP positions and 14 closed out — a net gain of 20 holders — while 48 added to existing stakes and 34 trimmed.
The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $9.23M. The largest seller was Consonance Capital Management, cutting an estimated $10.3M.
- 138 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2016, up from 121 in Q1 2016.
- Funds reported $313M of ANI Pharmaceuticals stock for Q2 2016, up 60% quarter-over-quarter.
- 34 funds opened new ANI Pharmaceuticals positions in Q2 2016 and 14 closed out, a net change of +20 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2016 was Fiera Capital (Canada), an estimated $9.23M added.
- The largest ANI Pharmaceuticals seller in Q2 2016 was Consonance Capital Management, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2016.